Plasma VEGF Concentrations and Ketamine’s Effects on Suicidal Ideation in Depression With Suicidal Ideation

Wei Zheng¹, Li-Mei Gu¹, Yan-Ling Zhou¹, Cheng-Yu Wang¹, Xiao-Feng Lan¹, Bin Zhang¹ and Yu-Ping Ning¹,²*

¹The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China, ²The First School of Clinical Medicine, Southern Medical University, Guangzhou, China

Objectives: Accumulating evidence supports a role for vascular endothelial growth factor (VEGF) in the pathogenesis of depression, but its relationship with the antisuicidal effects of ketamine is not clear. Our objective was to determine whether there was an association between the plasma VEGF (pVEGF) concentrations and the antisuicidal response to serial ketamine infusions.

Methods: Six ketamine infusions (0.5 mg/kg) over a 12-day period were administered to sixty depressed individuals suffering from suicidal ideation. The Hamilton Depression Rating Scale (HAMD) suicide item, the Montgomery-Åsberg Depression Rating Scale (MADRS) suicide item, and the Beck Scale for Suicide Ideation (SSI-part I) were used to assess suicidal ideation at baseline, 1 day after the first infusion (day 1), 1 day following the last infusion (day 13), and again 2 weeks post-infusion (day 26). For this purpose, plasma was obtained at baseline, day 13 and 26.

Results: The rates of antisuicidal response to ketamine were 61.7% (37/60), 81.7% (49/60), and 73.3% (44/60) at days 1, 13, and 26, respectively. The linear mixed model revealed significant time effects on suicidal ideation and pVEGF concentrations over time (all Ps < 0.05). Antisuicidal responders did not have significantly altered pVEGF concentrations compared with non-responders on day 13 and day 26 (all Ps > 0.05).

No significant correlation was found between the baseline pVEGF concentration and suicidal ideation as measured by the SSI part 1, HAMD suicide item and MADRS suicide item on days 1, 13, and 26 (all ps > 0.05).

Conclusion: This preliminary finding does not support a role for VEGF in the antisuicidal effects of serial ketamine treatments in individuals with depression and suicidal ideation. Further research is needed to confirm and expand these findings.

Keywords: ketamine, VEGF, suicidal ideation, depression, response
INTRODUCTION

Approximately 0.8 million individuals worldwide die by suicide every year (1), which is becoming a substantial public health concern. Suicide is a complex and multifaceted phenomenon where numerous potential mechanisms could be implicated (2). Suicidal ideation is common in individuals with major depressive disorder (MDD) (3) and bipolar depression (BD) (4), especially among inpatients. Better therapy for suicidal ideation in MDD and BD is a critical target in preventing deaths due to suicide (5). However, very few treatments can rapidly alleviate suicidal ideation (6). Although accumulating evidence has indicated that treatment with dialectical behavioral therapy (7), cognitive behavioral therapy (CBT) (8, 9), and lithium (10) can effectively alleviate suicidal ideation, the onset of clinically relevant antisuicidal effects generally takes 2–4 weeks. Thus, novel pharmacotherapeutic approaches are urgently needed for subjects with depression and suicidal ideation.

As a non-selective N-methyl-D-aspartic acid receptor (NMDAR) antagonist, ketamine has shown quick and dramatic antisuicidal effects in randomized controlled trials (RCTs) (11, 12) and meta-analyses (13, 14) for MDD and BD. In addition to its rapid antisuicidal effects, ketamine at a single intravenous dose has a rapid effect in reducing the level of depression (15–18) and ameliorating depressive symptoms (19, 20) in MDD and BD. After controlling for the effects of ketamine on depression, ketamine’s antisuicidal ideation remained significant (13, 21). Antidepressant and antisuicidal responses to a single ketamine infusion could be prolonged with repeated ketamine infusions (22, 23). For example, a recent study found that the antisuicidal response rates increased from 57.0% to 65.1% after five additional infusions of ketamine in depressed patients experiencing suicidal ideation (22). However, a certain proportion of depressed patients experiencing suicidal ideation do not adequately respond to single or repeated ketamine infusions, but the reasons for this are unclear.

Vascular endothelial growth factor (VEGF), as an angiogenic cytokine, has been associated with the antidepressant response to electroconvulsive therapy (ECT) (24) and serotonin selective reuptake inhibitors (SSRIs) (25). Patients experiencing suicidal ideation had lower cerebrospinal fluid VEGF concentrations than healthy controls (26). In contrast, antidepressant therapy can induce hippocampal expression of VEGF (27). Recently, Deyama et al. found that the rapid antidepressant response to ketamine was associated with neuronal VEGF-Flk-1 signaling in the medial prefrontal cortex (mPFC) (28). Finding on the relationship between VEGF and ketamine’s antidepressant effect in depressed patients were inconsistent (29, 30). For instance, McGrory et al. found that VEGF plays an essential role in the antidepressant action of ketamine (30). However, another study reported a negative finding (29). No study has yet reported on the association of plasma VEGF (pVEGF) concentrations and the antisuicidal effects of repeated-dose intravenous ketamine in Chinese subjects with depression who are experiencing suicidal ideation.

The aim of the current study was to: (1) detect the change in pVEGF concentrations after repeated-dose intravenous ketamine infusions of ketamine in depressed patients experiencing suicidal ideation and (2) to demonstrate the relationship between pVEGF concentrations and the antisuicidal effects of repeated doses of intravenous ketamine. We hypothesized that pVEGF concentrations would be increased after six ketamine infusions, and pVEGF would play an important role in the antidepressant actions of ketamine in individuals with depression and suicidal ideation.

METHODS

Study Population and the Procedure

The data for this study were obtained from a single-center clinical trial (Registration Number: ChiCTR-OOC-17012239) in which unipolar and bipolar depressed patients received six ketamine infusions at the Affiliated Brain Hospital of Guangzhou Medical University from September 2016 to December 2017 (31, 32). All patients gave written informed consent and the study was approved by the Affiliated Brain Hospital of Guangzhou Medical University Institutional Review Board (Ethical Application Ref: 2016030). In the present study, we specifically report the association between pVEGF concentration and the effect of ketamine on suicidal ideation, focusing on depressed patients with suicidal ideation. The inclusion criteria were as follows: (1) sixty depressed patients were 18–65 years old with suicidal ideation as defined by the Beck Scale for Suicide Ideation (SSI)-part I $\geq$ 2 (33, 34); (2) patients fulfilling the diagnostic criteria listed in the DSM-5, for MDD or BD without psychotic symptoms; (3) each participant experiencing a major depressive episode of at least moderate severity, as defined by the 17-item Hamilton Depression Rating Scale (HAMD) $\geq$ 17 (35, 36); (4) full understanding of the study procedure. The exclusion criteria of the current study were consistent with those used in previous studies (31, 32). Briefly, participants diagnosed with other psychiatric disorders such as schizophrenia, substance use disorder or alcohol use disorder were excluded, but a comorbidity of obsessive compulsive disorder, anxiety disorder or eating disorder was permitted when it was not judged to be the primary presenting problem. All subjects received six intravenous infusions of ketamine at subanaesthetic doses over 12 days. During the study period, the participants continued their psychotropic medications.

Antisuicidal Response

The SSI part I, the Montgomery-Åsberg Depression Rating Scale (MADRS) suicide item, and the HAMD suicide item were used to evaluate the severity of suicidal ideation at baseline, 1 day after the first infusion (day 1), 1 day after the completion of six ketamine infusions (day 13), and at the 2-week follow-up after the completion of six ketamine infusions (day 26). Antisuicidal responses to repeated-dose intravenous ketamine at day 13 were defined by the SSI part I $< 2$ (22, 37).

Measurement of pVEGF Concentrations

A commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, USA) was used to examine the pVEGF concentrations according to the manufacturer’s recommendations. The plasma was obtained at...
The measurement of the pVEGF concentrations was in line with those used in a recent study (29).

### Statistical Analysis

Data from this study were analyzed by using SPSS 24.0 statistical software. Significance was considered at $p < 0.05$. The demographic and clinical characteristics and pVEGF concentrations at baseline were compared between the antisuicidal responders and the non-responders using the chi-squared test and/or Fisher’s exact test for categorical variables and Student’s $t$-test and/or the Mann–Whitney U test for continuous variables, as appropriate. Changes in the pVEGF concentrations and the suicidal symptoms evaluated by the HAMD suicide item, MADRS suicide item, and SSI part I over time and the subgroup differences (antisuicidal responders vs.

### TABLE 1 | Baseline characteristics of antisuicidal responders and non-responders calculated by SSI part I scores on day 13.

| Variables | Total sample ($n = 60$) | Antisuicidal responders ($n = 49$) | Antisuicidal non-responders ($n = 11$) | Statistics |
|-----------|-------------------------|----------------------------------|-------------------------------------|------------|
|           | $N$ | %   | $N$ | %   | $N$ | %   | $X^2$ | df | $p$ |
| Male      | 27  | 45.0 | 22  | 44.9 | 5   | 45.5 | -a   | -a | 1.00 |
| Employed  | 23  | 38.3 | 21  | 42.9 | 2   | 18.2 | -a   | -a | 0.18 |
| Married   | 34  | 56.7 | 27  | 55.1 | 7   | 63.6 | -a   | -a | 0.74 |
| On ADs two or more | 8 | 13.3 | 8  | 16.3 | 0   | 0    | -a   | -a | 0.33 |
| On APs    | 35  | 58.3 | 29  | 59.2 | 6   | 54.5 | -a   | -a | 1.00 |
| On mood stabilizers | 16 | 26.7 | 13  | 26.5 | 3   | 27.3 | -a   | -a | 0.00 |
| On benzodiazepines | 27 | 45.0 | 21  | 42.9 | 6   | 54.5 | -a   | -a | 0.52 |
| On anxiolytics | 27 | 45.0 | 22  | 44.9 | 5   | 45.5 | -a   | -a | 1.00 |
| On anticholinergics | 8 | 13.3 | 8  | 16.3 | 0   | 0    | -a   | -a | 0.33 |

| Mean | SD | Mean | SD | Mean | SD | T/Z | df | $p$ |
|------|----|------|----|------|----|-----|----|-----|
| Age (years) | 35.3 | 12.4 | 34.8 | 12.0 | 37.4 | 14.4 | -0.6 | 58 | 0.54 |
| Education level (years) | 12.2 | 3.5 | 12.5 | 3.4 | 10.7 | 3.9 | 0.8 | 58 | 0.14 |
| BMI | 22.2 | 3.5 | 22.1 | 3.3 | 22.8 | 4.5 | -0.7 | 58 | 0.51 |
| Illness duration (months) | 91.5 | 80.0 | 81.5 | 69.1 | 135.9 | 110.2 | -2.1 | 58 | 0.04 |
| FLUeq (mg/day) | 35.6 | 20.7 | 35.8 | 21.7 | 34.5 | 16.2 | 0.2 | 58 | 0.85 |
| CPZeq (mg/day) | 169.1 | 117.6 | 168.7 | 125.8 | 170.8 | 74.5 | -0.5 | -b | 0.64 |
| Baseline pVEGF concentrations (ng/ml) | 38.4 | 55.7 | 44.5 | 59.7 | 11.6 | 15.7 | -1.8 | -b | 0.07 |
| Baseline SSI-part I scores | 5.0 | 2.4 | 4.8 | 2.5 | 5.2 | 2.2 | 0.34 | 58 | 0.73 |
| Baseline HAMD suicide item scores | 2.2 | 0.8 | 2.2 | 0.8 | 2.5 | 0.8 | -1.5 | 58 | 0.15 |
| Baseline MADRS suicide item scores | 2.9 | 1.3 | 2.8 | 1.2 | 3.5 | 1.5 | -1.8 | 58 | 0.07 |

Bolded values are $p < 0.05$.

*aFisher’s Exact Test.

*bMann-Whitney U test.

Ads, Antidepressants; APs, antipsychotics; BMI, body mass index; CPZeq, chlorpromazine equivalent milligrams; FLUeq, Fluoxetine equivalents equals; pVEGF, plasma vascular endothelial growth factor; df, degrees of freedom; HAMD, the Hamilton Depression Rating Scale; MADRS, the Montgomery–Åsberg Depression Rating Scale; SSI, the Beck Scale for Suicide Ideation; SD, standard deviation; TRD, treatment refractory depression.

### TABLE 2 | Comparison of suicidal ideation scores and pVEGF concentrations between antisuicidal responders and non-responders in depressed patients with suicidal ideation using linear mixed model analysis.

| Variables | Group-by-time interaction | Time main effect | Group main effect |
|-----------|---------------------------|-----------------|-----------------|
|           | $F$ | $p$ | $F$ | $p$ | $F$ | $p$ |
| HAMD suicide item scores | 6.8 | <0.001 | 33.2 | <0.001 | 11.9 | 0.001 |
| MADRS suicide item scores | 4.6 | 0.004 | 30.1 | <0.001 | 10.2 | 0.002 |
| SSI-part I scores | 4.1 | 0.008 | 28.8 | <0.001 | 11.2 | 0.002 |
| pVEGF concentrations (ng/ml) | 0.6 | 0.55 | 3.5 | 0.04 | 0.3 | 0.57 |

Bolded values are $p < 0.05$.

pVEGF, plasma vascular endothelial growth factor; SSI, the Beck Scale for Suicide Ideation; MADRS, the Montgomery–Åsberg Depression Rating Scale; HAMD, the Hamilton Depression Rating Scale.
FIGURE 1 | The antisuicidal effects of ketamine were measured by SSI part I, the MADRS suicide item, and the HAMD suicide item. The antisuicidal effects of ketamine as measured by SSI part I (A), the MADRS suicide item (B), and the HAMD suicide item (C). #A significant difference was found compared to the baseline at the indicated times ($P < 0.05$). *A significant difference was found between antisuicidal responders and non-responders at the indicated times ($P < 0.05$). SSI, the Beck Scale for Suicide Ideation; MADRS, the Montgomery-Åsberg Depression Rating Scale; HAMD, the Hamilton Depression Rating Scale.
non-responders) were investigated using linear mixed models. The association of pVEGF concentrations with the antisuicidal effects of ketamine was examined by correlation analysis.

RESULTS

pVEGF concentrations were obtained from 60 patients suffering from depression and suicidal ideation. A comparison between the demographic and clinical characteristics of antisuicidal responders and non-responders is presented in Table 1. Antisuicidal responders had marginally significantly higher baseline pVEGF concentrations than antisuicidal non-responders ($P = 0.07$; Table 1).

The rates of antisuicidal responses to ketamine were 61.7% (37/60), 81.7% (49/60), and 73.3% (44/60) on days 1, 13, and 26, respectively. The linear mixed model with SSI part I, MADRS suicide items and HAMD suicide items showed a significant main effect of time and group and a group-by-time interaction (all $P < 0.05$; Table 2). Antisuicidal responders had a significantly greater reduction in suicidal ideation than non-responders (as measured by the SSI part I, the MADRS suicide item and the HAMD suicide item) at days 1 and 13 (all $P < 0.05$; Figure 1). The linear mixed model with pVEGF concentrations showed a significant main effect of time ($P < 0.05$; Table 2) but not for the main effect of group and group-by-time interaction (all $P > 0.05$; Table 2). Although a significant change in pVEGF concentrations was found at day 26 as compared to baseline ($P < 0.05$), the antisuicidal responders compared to nonresponders did not have significantly altered pVEGF concentrations at day 13 and day 26 (all $P > 0.05$; Figure 2).

As depicted in Table 3, no significant association of baseline pVEGF concentrations and reductions in suicidal ideation following ketamine treatment (as measured by the SSI part I, the

TABLE 3 | Correlation analysis between suicidal ideation and baseline pVEGF concentrations in depressed patients with suicidal ideation at the indicated times.

| Variables                                      | HAMD suicide item scores | MADRS suicide item scores | SSI-part I scores |
|------------------------------------------------|--------------------------|---------------------------|-------------------|
|                                                | Day 1        | Day 13       | Day 26       | Day 1     | Day 13    | Day 26       | Day 1    | Day 13    | Day 26       |
| Baseline pVEGF concentrations (ng/ml)           |              |              |              | $r$       | $p$       | $r$       | $p$       | $r$       | $p$       |
| $r$                                            | −0.07        | −0.18        | 0.16         | −0.05     | −0.19     | 0.13       | 0.17     | −0.22     | 0.24       |
| $p$                                            | 0.62         | 0.22         | 0.30         | 0.74      | 0.19      | 0.41       | 0.20     | 0.09      | 0.07       |
| Change in pVEGF concentrations (ng/ml)          |              |              |              | $r$       | $p$       | $r$       | $p$       | $r$       | $p$       |
| $r$                                            | 0.10         | −0.14        | 0.09         | 0.09      | −0.10     | 0.07       | 0.10     | −0.24     | −0.02      |
| $p$                                            | 0.53         | 0.36         | 0.54         | 0.59      | 0.51      | 0.67       | 0.53     | 0.11      | 0.91       |

pVEGF: plasma vascular endothelial growth factor; $r$: Pearson coefficient of correlation; SSI, the Beck Scale for Suicide Ideation; MADRS, the Montgomery-Åsberg Depression Rating Scale; HAMD, the Hamilton Depression Rating Scale.

FIGURE 2 | The change in pVEGF concentrations in depressed patients with suicidal ideation at the indicated times. No significant difference at the indicated times was found when compared to baseline ($P > 0.05$). No significant difference at the indicated times was found between antisuicidal responders and non-responders ($P > 0.06$). pVEGF, plasma vascular endothelial growth factor.
MADRS suicide item, and the HAMD suicide item) were found on day 1, day 13, or day 26 (all $P_s > 0.05$; Table 2).

**DISCUSSION**

The current study first illuminated the association of pVEGF concentrations with the effect of ketamine on suicidal ideation. Our findings indicate that antisuicidal responders had marginally significantly greater pVEGF concentrations at baseline than antisuicidal non-responders. Despite a significant reduction in suicidal ideation during serial ketamine infusions over time, the pVEGF concentrations were not significantly altered in antisuicidal responders compared with non-responders on day 13 and day 26. Similarly, no notable association was detected between the pVEGF concentrations and the effects of repeated-dose intravenous ketamine on suicidal ideation as measured by SSI part I, the MADRS suicide item, and the HAMD suicide item.

Accumulating evidence suggests that VEGF is associated with brain function, including neurogenesis, learning and memory, by regulating hippocampal synaptic activity and plasticity (38–41). Dysregulated VEGF concentrations have been involved in major mental disorders, such as MDD and BD (42). Low pVEGF concentrations are associated with a higher suicide risk among suicide attempters (43). Therapy with antidepressants such as SSRIs (27, 44) and ketamine (30) can increase the expression of VEGF. Consistent with previous studies (11–14), in this study, ketamine had a rapid and robust effect in reducing suicidal ideation. Repeated administration of intravenous ketamine (0.5 mg/kg) did not significantly increase pVEGF concentrations, even after a 2-week follow-up, corroborating the results of previous studies (45).

As reported by Deyama et al.’s study, the antidepressant-like and neurotrophic actions of brain-derived neurotrophic factor (BDNF) require VEGF signaling (44). Thus, VEGFR2 signaling appears to be indispensable for cellular and behavioral responses to antidepressant treatments (27). The findings of several animal trials support a role for VEGF in the biological actions of antidepressants (i.e., fluoxetine) (46) and mood stabilizers (i.e., lamotrigine) (47). Similarly, VEGF could mediate the antidepressant actions of electroconvulsive seizures (48, 49) and a single ketamine infusion (28) but not six ketamine infusions (29). However, in this study, we found that VEGF was not involved in the antisuicidal effects of repeated-dose intravenous ketamine in Chinese patients with depression and suicidal ideation, which should be confirmed by RCTs.

This study is associated with several limitations. First, the relatively small sample size is the first study limitation, partly accounting for the negative results. Second, the lack of a control group in the protocol of the present study was another limitation, affecting the interpretation and external validity of the findings. Third, when compared to the samples from controlled clinical trials, the sample of the current study based on a real-world design is potentially more heterogeneous. Furthermore, the pooling of subjects suffering from MDD and BD made the sample non-homogeneous. Fourth, although substance use disorder is a significant predictor of non-adherence among individuals suffering from mood disorders (50), patients suffering from substance use disorder were excluded in this study. Finally, all subjects continued to receive psychotropic medications, which may have potentially affected their pVEGF concentrations and explained the contradictory findings between this study and previous studies (30, 45). Finally, as reported by Levy et al., blood VEGF concentrations may not be associated with VEGF concentrations in the brain (51). However, VEGF concentrations in the brain could not be directly detected in the current study.

**CONCLUSIONS**

This preliminary study does not support a role for VEGF in the antisuicidal effects of serial ketamine treatments in individuals with depression and suicidal ideation. Further research is needed to confirm and expand these findings.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Affiliated Brain Hospital of Guangzhou Medical University Institutional Review Board (Ethical Application Ref: 2016030). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Y-PN: study design. WZ, Y-LZ, C-YW, and X-FL: data collection. WZ and L-MG: analysis and interpretation of data. WZ: drafting of the manuscript. BZ and Y-PN: critical revision of the manuscript. All authors: approval of the final version for publication.

**FUNDING**

This study was funded by the National Natural Science Foundation of China (82101609), Scientific Research Project of Guangzhou Bureau of Education (202032762), Science and Technology Program Project of Guangzhou (202102020658), the Science and Technology Planning Project of Liwan District of Guangzhou (202004034), Guangzhou Health Science and Technology Project (20211A011045), Guangzhou science and Technology Project of traditional Chinese Medicine and integrated traditional Chinese and Western Medicine (20212A011018), China International Medical Exchange Foundation (Z-2018-35-2002), Guangzhou Clinical Characteristic Technology Project (2019T567), and Science and Technology Program Project of Guangzhou (202102020658). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
REFERENCES

1. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. *World Psychiatry*. (2014) 13:153–60. doi: 10.1016/j.wpsyc.2013.11.016

2. Orsolini L, Latini R, Pompili M, Serafini G, Volpe U, Vellante F, et al. Understanding the complex of suicide in depression: from research to clinics. *Psychiatry Investig*. (2020) 17:207–21. doi: 10.30773/pi.2019.01717

3. Cai H, Jin Y, Liu S, Zhang Q, Zhang L, Cheung T, et al. Prevalence of suicidal ideation and planning in patients with major depressive disorder: a meta-analysis of observational studies. *Epidemiol Psychiatr Sci*. (2019) 29:63. doi: 10.1016/S20457960(19)000593.

4. Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. *J Affect Disord*. (2017) 218:195–200. doi: 10.1016/j.jad.2017.04.0577

5. Griffiths JR, Zarate CA, Jr., Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. *Am J Prev Med*. (2014) 47 (3 Suppl. 2):S195–203. doi: 10.1016/j.amepre.2014.06.012

6. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard KJ, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. *Arch Gen Psychiatry*. (2006) 63:757–66. doi: 10.1001/archpsyc.63.7.757

7. Griffiths JR, Zarate CA, Jr., Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. *Am J Prev Med*. (2014) 47 (3 Suppl. 2):S195–203. doi: 10.1016/j.amepre.2014.06.012

8. Brown GK, Ten Have T, Henriques GR, Xie SX, Hollander JE, Beck AT. Antidepressant effects of ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. *Psychol Med*. (2016) 46:1459–72. doi: 10.1017/S0033291716000064

9. Dong M, Lu L, Zhang L, Zhang Q, Ungvari GS, Ng CH, et al. Prevalence of suicidal ideation and planning in patients with major depressive disorder: a systematic review and meta-analysis of observational studies. *Depress Anxiety*. (2012) 25:84–92. doi: 10.1002/da.21830

10. Zhou Y, Liu W, Zheng W, Wang CY, Zhan YN, Li HQ, et al. Rapid and long-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. *Biol Psychiatry*. (2013) 74:250–6. doi: 10.1016/j.biopsych.2012.06.022

11. Ballard ED, Ionescu DF, Vande Voort JL, Nicu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. *J Psychiatr Res*. (2014) 58:161–6. doi: 10.1016/j.jpsychires.2014.07.027

12. Zheng W, Zhou Y, Zhan Y, Zheng R, Liu W, Wang C, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. *J Affect Disord*. (2019) 251:205–12. doi: 10.1016/j.jad.2019.03.071

13. Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, et al. Rapid and long-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. *Biol Psychiatry*. (2013) 74:250–6. doi: 10.1016/j.biopsych.2012.06.022

14. Minelli A, Maffioletti E, Bortolomasi M, Conca A, Zanardini R, Rillosi L, et al. Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. *Acta Psychiatr Scand*. (2014) 129:461–6. doi: 10.1111/acps.12187

15. Kao CE, Liu YL, Yu YW, Yang AC, Lin E, Kuo PH, et al. Gene-based analysis of genes related to neurotrophic pathway suggests association of BDNF and VEGFA with antidepressant treatment-response in depressed patients. *Sci Rep*. (2018) 8:6983. doi: 10.1038/s41598-018-25529-9

16. Isung J, Ainehandb S, Morabar Z, Martinsson B, Nordstrom P, Asberg M, et al. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. *Transl Psychiatry*. (2012) 2:e196. doi: 10.1038/tip.2012.123

17. Nowacka MM, Obuchowicz E. Vascular endothelial growth factor (VEGF) and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. *Neuropeptides*. (2012) 46:1–10. doi: 10.1007/s11065-011-0005-5

18. Deyama S, Wang MC, Wehle E, Li X, Kato T, Gerhard DM, et al. Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. *Am J Psychiatry*. (2019) 176:388–400. doi: 10.1176/appi.ajp.2018.17121368

19. Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Zhou SM, et al. Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression. *Therap Adv Psychopharmacol*. (2021) 11:20451253211014320. doi: 10.1177/20451253211014320

20. McGrory CL, Ryan KM, Gallagher B, McLoughlin DM. Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine. *J Affect Disord*. (2020) 273:380–3. doi: 10.1016/j.jad.2020.04.013

21. Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. *J Psychopharmacol*. (2019) 33:494–501. doi: 10.1177/0269881119827811

22. Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and long-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. *J Psychiatr Res*. (2018) 106:61–8. doi: 10.1016/j.jpsychires.2018.09.013

23. Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Nicu MJ, et al. Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. *J Clin Psychiatry*. (2017) 78:1068–74. doi: 10.4088/JCP.15m10440

24. Zhou Y, Liu W, Zheng W, Wang C, Zhan Y, Lan X, et al. Predictors of response to repeated ketamine infusions in depression with suicidal ideation: an ROC curve analysis. *J Affect Disord*. (2020) 264:263–71. doi: 10.1016/j.jad.2020.01.001

25. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry*. (1960) 23:56–62. doi: 10.1136/jnnp.23.1.56
36. Xie GR, Shen QJ. Use of the Chinese version of the Hamilton Rating Scale for Depression in general population and patients with major depression (In Chinese). Chin J Nerv Ment Dis. (1984) 10:364.

37. Rasmussen KG, Lineberry TW, Galardy CW, Kung S, Lapid MI, Palmer BA, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol. (2013) 27:444–50. doi: 10.1177/0269881113478283

38. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet. (2004) 36:827–35. doi: 10.1038/ng1395

39. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. (2004) 26:943–54. doi: 10.1002/bies.20092

40. Fournier NM, Lee B, Banasr M, Elsayed M, Duman RS. Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology. (2012) 65:642–52. doi: 10.1016/j.neuropharm.2012.04.033

41. Calvo CF, Fontaine RH, Soueid J, Tammela T, Makinen T, Alfaro-Cervello C, et al. Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. Genes Dev. (2011) 25:831–44. doi: 10.1101/gad.615311

42. Clark-Raymond A, Halaris A. VEGF and depression: a comprehensive assessment of clinical data. J Psychiatr Res. (2013) 47:1080–7. doi: 10.1016/j.jpsychires.2013.04.008

43. Isung J, Mobarrez F, Nordström P, Asberg M, Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. (2012) 13:486–73. doi: 10.3109/15622975.2011.624549

44. Deyama S, Bang E, Kato T, Li XY, Duman RS. Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor. Biol Psychiatry. (2019) 86:143–52. doi: 10.1016/j.biopsych.2018.12.014

45. Medeiros GC, Greenstein D, Kadriu B, Yuan P, Park LT, Gould TD, et al. Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. (2021) 280:136–9. doi: 10.1016/j.jad.2020.11.011

46. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. (2009) 34:2459–68. doi: 10.1038/npp.2009.68

47. Sun R, Li N, Li T. VEGF regulates antidepressant effects of lamotrigine. Eur Neuropsychopharmacol. (2012) 22:424–30. doi: 10.1016/j.euroneuro.2011.09.010

48. Segi-Nishida E. Exploration of new molecular mechanisms for antidepressant actions of electroconvulsive seizure. Biol Pharm Bull. (2011) 34:939–44. doi: 10.1248/bpb.34.939

49. Warner-Schmidt JL, Duman RS. VEGF as a potential target for therapeutic intervention in depression. Curr Opin Pharmacol. (2008) 8:14–9. doi: 10.1016/j.coph.2007.10.013

50. Pompili M, Venturini P, Palermo M, Stefani H, Seretti ME, Lamis DA, et al. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother. (2013) 13:809–25. doi: 10.1586/14737175.2013.811976

51. Levy MJF, Boullé F, Steinbusch HW, van den Hove DLA, Kenis G, Lanfumey L. Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. (2018) 235:2195–220. doi: 10.1007/s00213-018-4950-4

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Gu, Zhou, Wang, Lan, Zhang and Ning. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.